The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Youngil Koh
No relevant relationships to disclose
Keun-Wook Lee
No relevant relationships to disclose
Sung-Bae Kim
No relevant relationships to disclose
Kyong Hwa Park
No relevant relationships to disclose
Sang Won Shin
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Bhumsuk Keam
No relevant relationships to disclose
Se-Hoon Lee
No relevant relationships to disclose
Dae Seog Heo
No relevant relationships to disclose